BridgeBio Pharma (BBIO) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BridgeBio Pharma (BBIO) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 22.6% versus a loss of 12.5%. Over five years, BBIO leads with a +38.6% price change compared with -7.1% for RDY. BridgeBio Pharma is the larger company by market cap ($13.00 billion vs $10.22 billion), about 1.3 times the size.
On valuation, Dr. Reddy's Laboratories trades at a lower forward P/E (19.0x vs 2420.8x for BridgeBio Pharma). Dr. Reddy's Laboratories pays a dividend yielding 65.20%, while BridgeBio Pharma does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus -146.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | RDY |
|---|---|---|
| Share price | $66.50 | $12.27 |
| Market cap | $13.00B | $10.22B |
| 1-day change | -0.69% | -1.76% |
| YTD return | -13.06% | -12.61% |
| 1-year return | +22.65% | -12.54% |
| 5-year return | +38.60% | -7.06% |
| P/E ratio (TTM) | — | 27.89 |
| Forward P/E | — | 19.05 |
| EPS (TTM) | $-3.56 | $0.44 |
| Dividend yield | 0.00% | 65.20% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | $502.08M | $3.81B |
| Revenue growth (YoY) | +126.26% | +13.76% |
| Net income (latest FY) | $-732.94M | $663.00M |
| Gross margin | 95.82% | 58.51% |
| Operating margin | -104.25% | 22.09% |
| Net margin | -145.98% | 17.40% |
| 52-week high | $93.42 | $15.67 |
| 52-week low | $52.75 | $11.36 |
| Distance from 52-week high | -28.81% | -21.70% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +63.98% | +7.74% |
| Average volume | 2.76M | 2.89M |
| Shares outstanding | 195.49M | 832.99M |
| Employees | 999 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BBIO has outperformed RDY by 35.2 percentage points over the past year.
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (65.20% vs 0.00%).
- Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
- BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +13.76%).
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 999 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
BBIO vs RDY FAQ
Which is bigger, BridgeBio Pharma or Dr. Reddy's Laboratories?
BridgeBio Pharma (BBIO) is larger, with a market capitalization of $13.00B compared with $10.22B for Dr. Reddy's Laboratories (RDY).
Which stock has performed better over the past year, BBIO or RDY?
BBIO returned +22.65% over the past 12 months, compared with -12.54% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, BridgeBio Pharma or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 65.20%, while BridgeBio Pharma does not currently pay a regular dividend.
Are BridgeBio Pharma and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.